Effect of hypofractionated simultaneous integrated boost radiotherapy on immune function in patients with breast cancer
10.3760/cma.j.cn113030-20230817-00053
- VernacularTitle:乳腺癌全乳大分割放疗同步瘤床加量对免疫功能的影响
- Author:
Yang ZHOU
1
;
Jingjing LIU
;
Xiaohong WANG
;
Na LI
;
Bin LI
;
Yufeng LI
Author Information
1. 河北省分子肿瘤学重点实验室，唐山市人民医院中心实验室，唐山 063001
- Keywords:
Breast neoplasms;
Radiotherapy, hypofractionated intensity modulated;
Simultaneous integrated boost;
Sequential boost;
Immune function
- From:
Chinese Journal of Radiation Oncology
2024;33(7):627-633
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the effect of simultaneous integrated boost verse sequential boost in hypofractionated radiotherapy on immune function in patients with breast cancer after breast-conserving surgery.Methods:Clinical data of 200 patients with breast cancer undergoing breast-conserving surgery in Tangshan People's Hospital from January 2021 to April 2023 were retrospectively analyzed. All patients were divided into the simultaneous integrated boost group and sequential boost group (control) with 100 patients in each group according to the dosage method of the tumor bed. Both groups of patients received hypofractionated radiotherapy with the whole breast radiation dose of 43.5 Gy in 15 fractions. The tumor bed dose for the simultaneous integrated boost group and sequential boost group were 49.5 Gy in 15 fractions and 8.7 Gy in 3 fractions, respectively. Changes in peripheral lymphocyte counts (PLC) and T lymphocyte subsets before and after radiotherapy were compared between two groups using t-test. Results:Before radiotherapy, the baseline PLC, CD3 +T lymphocytes, CD4 +T lymphocytes, CD8 +T lymphocytes and CD4 +/CD8 + were comparable between two groups (all P>0.05). After radiotherapy, the PLC,CD3 +T lymphocytes, CD4 +T lymphocytes and CD8 +T lymphocytes were decreased in both groups, but CD4 +/CD8 + did not change. There were no statistical significances in PLC [(1.01±0.29)×10 9/L vs. (1.08±0.40)×10 9/L],CD3 +T lymphocytes [(557.77±152.29) vs. (555.17±162.31) /μl], CD4 +T lymphocytes [(312.29±120.78) vs. (295.17±106.81) /μl], CD8 +T lymphocytes [(211.77±62.88) vs. (223.94±1.69) /μl] and CD4 +/CD8 + (1.54±0.46 vs. 1.39±0.52) between two groups(all P>0.05). Conclusion:There is no difference in PLC and T lymphocyte subsets between the simultaneous integrated boost and sequential boost in hypofractionated radiotherapy for patients after breast-conserving surgery.
